Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots.
The US Food and Drug Administration approved Cambridge, Massachusetts-based Moderna’s vaccine against respiratory syncytial virus, a flu-like illness that affects elderly adults and babies most severely, according to a statement Friday. The decision had earlier been expected by May 12, and was delayed because of “administrative constraints” at the agency, Moderna said earlier this month.
Moderna’s shot, called mRESVIA, was…
